Skip to main content
Equibles
SER logo

SER · Serina Therapeutics, Inc. · Metrics

Track SER — free

Use SER with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SER.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.73 +0.09 (+5.49%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has concluded that our existing cash and cash equivalents are not expected to be sufficient to fund our operations for the 12 months following the issuance of our unaudited condensed consolidated financial statements for the period ended June 30, 2026, and that substantial doubt about our ability to continue as a going concern continues to exist.”
View the 10-Q filed Aug 13, 2026
Market Cap
$44.45M
Shares
25.40M
Volume · Oct 29 18.31K Avg daily vol (3M) 66.26K

SER metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.64
Market cap
$44.45M

Price action

20 metrics
Price change (1W)
-7.3%
Price change (30D)
-21.2%
Price change (3M)
-20.8%
Price change (6M)
-10.4%
Price change (YTD)
-14.3%
Price change (1Y)
-67.8%
Trailing year
Price change (5Y)
—
52-week high
$5.09
52-week low
$1.28
Change from 52-week high
-67.8%
Change from 52-week low
+28.1%
Annualized volatility
138.4%
Annualized volatility (3M)
71.7%
Beta
1.6
RSI (14D)
34.8
Price vs SMA 50
-24.8%
Price vs SMA 200
-21.8%
Avg volume (3M)
66,256
Relative volume
0.4
Average dollar volume
$150,721

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
25.40M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.2
reciprocal yield 44.8%
FCF yield
-50.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-50.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
875.9×
reciprocal yield 0.1%
EV / revenue historical average (5Y)
875.9×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
-14,755.4%
Gross profit (TTM)
$102,000
Operating profit (TTM)
−$25.66M
Net income (TTM)
−$21.17M
Trailing 12 months
Diluted EPS (TTM)
$-1.89
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.72
Operating cash flow per diluted share (TTM)
$-1.73
Free cash flow per diluted share (TTM)
$-1.73
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.17
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+63.8%
Year over year · more shares
Revenue CAGR (3Y)
+56.4%
Revenue CAGR (5Y)
-18.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-113.0%
Return on assets
-82.0%
Debt / equity
—
Current ratio
6.7
EBITDA (TTM)
−$25.56M
Free cash flow (TTM)
−$21.20M
Quick ratio
6.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$23.02M
Total assets
$25.81M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$21.14M
Capital expenditures (TTM)
$66,000
R&D (TTM)
$14.07M
SG&A (TTM)
—
Stock compensation (TTM)
$3.50M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
27
13F filer change QoQ
+2
Institutional ownership
5.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
7.5%
Private-fund adviser ownership
0.7%
Active holders' share change QoQ
-1.7%
Holder tenure
2.7
Price vs estimated holder cost
-30.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.8%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1708599 CUSIP 81751A108 13F (30d) 5 filings 5 filers Visit website Investor relations